JAK inhibitors and COVID-19Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu
22 April 2022
Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysisYifei Ma, Nianqi Liu, Youlong Wang, Jiling Zeng, Ying-Ying Hu, Wu Hao, Huazheng Shi, Pengfei Zhu, Jun Lv, Wei Fan, Xinjia Wang
29 November 2021
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsBenjamin Switzer, John Haanen, Paul C Lorigan, Igor Puzanov, Samra Turajlic
16 July 2021
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapiesJason D Goldman, Philip C Robinson, Thomas S Uldrick, Per Ljungman
11 June 2021
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patientsEmanuela Romano, Steve Pascolo, Patrick Ott
11 June 2021
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapyLorenzo Iovino, Laurel A Thur, Sacha Gnjatic, Aude Chapuis, Filippo Milano, Joshua A Hill
13 May 2021
Immune profiling of COVID-19: preliminary findings and implications for the pandemicHolden T Maecker
7 May 2021
Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerationsMuhammad Bilal Abid
30 April 2021
IL-6 modulation for COVID-19: the right patients at the right time?Paolo Antonio Ascierto, Binqing Fu, Haiming Wei
9 April 2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory ScoreGino M Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C T Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-LumsdenSee the full list of authors
22 March 2021